Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr Donington on the Evolving Use of Perioperative Nivolumab in Resectable NSCLC

July 22nd 2025, 11:00pm

Bridging the Gaps in Lung Cancer

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC

July 18th 2025, 9:25pm

Kidney Cancer Research Summit

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC

July 18th 2025, 9:19pm

Kidney Cancer Research Summit

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC

July 18th 2025, 7:02pm

Kidney Cancer Research Summit

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC

July 18th 2025, 6:38pm

Kidney Cancer Research Summit

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC

July 18th 2025, 5:57pm

Kidney Cancer Research Summit

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Dr Runcie on Treatment Approaches in RCC After Progression on Adjuvant Therapy

July 18th 2025, 3:05pm

Kidney Cancer Research Summit

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC

July 18th 2025, 2:47pm

Kidney Cancer Research Summit

Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.

Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC

July 18th 2025, 2:24pm

Kidney Cancer Research Summit

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

July 17th 2025, 11:26pm

Kidney Cancer Research Summit

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Dr Machaalani on the Potential Role of Circulating KIM-1 as a Biomarker in Metastatic RCC

July 17th 2025, 11:15pm

Kidney Cancer Research Summit

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity

July 17th 2025, 8:34pm

Kidney Cancer Research Summit

David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.

Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management

July 17th 2025, 8:33pm

Kidney Cancer Research Summit

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025, 9:08pm

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC

July 11th 2025, 7:31pm

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025, 8:34pm

ESMO Gastrointestinal Cancers Congress

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

July 7th 2025, 8:15pm

ESMO Gastrointestinal Cancers Congress

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025, 4:44pm

ESMO Gastrointestinal Cancers Congress

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

July 7th 2025, 4:26pm

ESMO Gastrointestinal Cancers Congress

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025, 6:06pm

ESMO Gastrointestinal Cancers Congress

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

x